Table 4.
Results of mSEPT9 and CEA in colorectal cancer patients after surgery.
| Cases | Time Point # | Positive mSEPT9 | Negative mSEPT9 | Positive CEA | Negative CEA | P Value * | |
|---|---|---|---|---|---|---|---|
| All patients after surgery | 6 M | 38 (44.7%) | 47 (55.3%) | 22 (28.2%) | 56 (71.8%) | 0.035 | |
| 12 M | 27 (51.9%) | 25 (48.1%) | 23 (31.9%) | 49 (68.1%) | 0.028 | ||
| 18 M | 15 (46.9%) | 17 (53.1%) | 18 (32.1%) | 38 (67.9%) | 0.180 | ||
| 24 M | 7 (63.6%) | 4 (36.4%) | 14 (34.1%) | 27 (65.9%) | 0.095 | ||
| Patients without recurrence | 6 M | 34 (44.7%) | 42 (55.3%) | 19 (27.1%) | 51 (72.9%) | 0.038 | |
| 12 M | 25 (51.0%) | 24 (49.0%) | 20 (30.3%) | 46 (69.7%) | 0.033 | ||
| 18 M | 11 (40.7%) | 16 (59.3%) | 15 (28.3%) | 38 (71.7%) | 0.316 | ||
| 24 M | 7 (63.6%) | 4 (36.4%) | 14 (34.1%) | 27 (65.9%) | 0.095 | ||
| Patients with recurrence | 6 M | 4 (50.0%) | 4 (50.0%) | 3 (37.5%) | 5 (62.5%) | 1.0 | |
| 12 M | 1 (50.0%) | 1 (50.0%) | 2 (40.0%) | 3 (60.0%) | 1.0 | ||
| 18 M | 4 (80.0%) | 1 (20.0%) | 3 (100.0%) | 0 (0.0%) | 1.0 | ||
| 24 M | 0 | 0 | 0 | 0 | NA | ||
mSEPT9, methylated septin 9; CEA, carcinoembryonic antigen; M, month.
#Time point was arranged as a time period, for example, 6 M concluded samples tested at 3 M and 6 M.
*P Value is the difference of negative percentages between mSEPT9 and CEA.